UNSPSC 51144127: Lisdexamfetamine dimesylate

This classification denotes a cns stimulant and anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SJT761GEGS. European Medicines Agency schedules Lisdexamfetamine dimesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32146. Lisdexamfetamine dimesylate generally arises in the molecular formula C15H25N3O.2CH4O3S. The term 'lisdexamfetamine dimesylate' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule lisdexamfetamine dimesylate under HS 29242990.

As of Q4 2014, LISDEXAMFETAMINE DIMESYLATE remains US FDA's Preferred Term for this commodity. Lisdexamfetamine dimesylate bears US NLM identifiers UMLS ID C1739826 and NCI Concept Code C76628. SMILES: C[C@@H](CC1CCCCC1)NC(=O)[C@H](CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O.

UNSPSC 51144127 Lisdexamfetamine dimesylate is a Commodity code covering a specific prescription stimulant pharmaceutical product. State and local procurement under this code focuses on the acquisition of this drug and related pharmaceutical products through structured competitive bidding and cooperative purchasing frameworks, often bundled with broader pharmacy benefit management initiatives or multi-source generic pharmaceutical contracts that serve health departments, county health systems, and state human services agencies supporting community health programs.

Activity under the code spans county health departments and state health and human services commissions, with recent opportunities concentrated in Florida and Minnesota through both direct-purchase solicitations and multi-jurisdictional cooperative purchasing arrangements. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries (response deadline July 26, 2023), a procurement designed to support community health initiatives with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026; the RFP requires compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, pricing through three authorized wholesalers, and a 3 percent administrative fee, with contract awards effective July 1, 2026. The Texas Health and Human Services Commission also issued a Request for Information (HHS0017013) on April 3, 2026, exploring direct-to-manufacturer prescription programs to improve fulfillment efficiency and cost management outside traditional pharmacy benefit manager and group purchasing organization channels. Opportunities reflect both transactional pharmaceutical procurement and exploratory initiatives to reshape pharmacy benefit delivery models within state and local health systems.